Test Price
2,800 AED✅ Home Collection Available
IDH2 Gene Exon 4 Sequencing (NGS) in UAE | 2800 AED
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Genetic Counseling for result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The IDH2 gene exon 4 sequencing test uses targeted next-generation sequencing (NGS) to detect clinically actionable mutations such as R140Q and R172K within the fourth exon of the IDH2 gene. These mutations are critical biomarkers for diagnosing and managing acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Detection of specific IDH2 variants guides targeted therapy decisions, including the use of IDH inhibitors like enasidenib, and informs prognosis. This assay is performed on the Illumina® platform and analyzed by DHA-certified molecular pathologists to ensure maximum accuracy and clinical relevance.
| Feature | Our NGS Exon 4 Test | Standard Sanger Sequencing |
|---|---|---|
| Methodology | Targeted NGS (Illumina® platform) | Single-gene Sanger sequencing |
| Sensitivity | >99.9% for clinically relevant variants | ~98% |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks |
| Price | 2,800 AED | Variable; often similar without comprehensive coverage |
Physician Insight & Safety Protocols
“Genetic testing for IDH2 mutations provides pivotal molecular information that can shape treatment strategies for AML and MDS. However, no single laboratory result replaces the comprehensive clinical assessment. I strongly advise patients to review their full hematologic profile with their treating oncologist before making any therapeutic decisions.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory & Safety Protocol
Important Clinical Advisory
Do not discontinue or alter any prescribed medication, including targeted therapies such as enasidenib, without direct consultation with your qualified physician. Treatment decisions must always be guided by a complete clinical picture and specialist oversight.
Exclusion Criteria & Safety Precautions
Safety & Exclusion Criteria
- This test requires informed consent. For minors, consent must be provided by a legal guardian in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Individuals with active bleeding disorders or who are on anticoagulant therapy must inform the phlebotomist prior to blood collection.
- Emergency Red Flags: Seek immediate medical attention if you experience severe bleeding, unexplained bruising, dizziness, or signs of infection after the blood draw.
Patient FAQ & Clinical Guidance
1. What is the IDH2 gene exon 4 sequencing test and why is it performed?
IDH2 exon 4 sequencing pinpoints IDH2 mutations linked to acute myeloid leukemia and myelodysplastic syndromes. This targeted NGS test analyzes the fourth exon of the IDH2 gene, where the most clinically actionable mutations (e.g., R140, R172) reside. It guides treatment with IDH inhibitors like enasidenib and informs prognosis. Results are interpreted by DHA-certified molecular pathologists in conjunction with your oncologist. For more information, ask about our genetic counseling session.
2. What conditions require IDH2 exon 4 sequencing?
IDH2 exon 4 sequencing is used to confirm a diagnosis of AML or MDS and to guide targeted therapy. This test is typically ordered when AML or MDS is suspected based on clinical presentation, blood counts, or bone marrow biopsy. It may also be used to assess risk of disease progression or to monitor for clonal evolution. Results must always be interpreted by a qualified oncologist or hematologist within the full clinical context.
3. How should I prepare for the IDH2 exon 4 sequencing test?
No special preparation is required; provide a blood sample after informed consent and genetic counseling. Fasting is not necessary. A pre-test genetic counseling session is mandatory to review your family pedigree and explain the implications of the results. You may opt for a finger-prick blood spot on an FTA card or a standard venous blood draw. Our VIP mobile phlebotomy team collects samples between 8 AM and 11 PM daily. Ensure you share all relevant medications and clinical history.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This service strictly complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic information is handled with the highest confidentiality and security standards. Laboratory accredited to ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | IDH2 Gene Exon 4 Sequencing (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood or FTA Card Dried Blood Spot |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) on Illumina® Platform |
| ICD-10-CM Code | C92.00, D46.9 |
| LOINC Code | 92618-6 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians